MX2023000439A - Formulaciones a largo plazo. - Google Patents

Formulaciones a largo plazo.

Info

Publication number
MX2023000439A
MX2023000439A MX2023000439A MX2023000439A MX2023000439A MX 2023000439 A MX2023000439 A MX 2023000439A MX 2023000439 A MX2023000439 A MX 2023000439A MX 2023000439 A MX2023000439 A MX 2023000439A MX 2023000439 A MX2023000439 A MX 2023000439A
Authority
MX
Mexico
Prior art keywords
long
acting formulations
pharmaceutical compositions
bedaquiline
peg4000
Prior art date
Application number
MX2023000439A
Other languages
English (en)
Inventor
René Holm
Miriam Colombo
Wenyu Dong
Vervoort Iwan Caroline F
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023000439A publication Critical patent/MX2023000439A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Esta invención se refiere a composiciones farmacéuticas para la administración por vía intramuscular o inyección subcutánea, que comprende micro o nanopartículas del compuesto bedaquilina anti-TB, suspendido en un vehículo acuoso farmacéuticamente aceptable, y que comprende PEG4000 como un modificador de superficie, y al uso de tales composiciones farmacéuticas en el tratamiento y profilaxis de una infección por micobacterias patógenas.
MX2023000439A 2020-07-09 2021-07-08 Formulaciones a largo plazo. MX2023000439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20185105 2020-07-09
PCT/EP2021/068956 WO2022008643A1 (en) 2020-07-09 2021-07-08 Long-acting formulations

Publications (1)

Publication Number Publication Date
MX2023000439A true MX2023000439A (es) 2023-02-09

Family

ID=71575093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000439A MX2023000439A (es) 2020-07-09 2021-07-08 Formulaciones a largo plazo.

Country Status (12)

Country Link
US (1) US20230241051A1 (es)
EP (1) EP4178546A1 (es)
JP (1) JP2023533014A (es)
KR (1) KR20230038521A (es)
CN (1) CN115867259A (es)
AU (1) AU2021303490A1 (es)
BR (1) BR112023000220A2 (es)
CA (1) CA3182425A1 (es)
CO (1) CO2023001340A2 (es)
MX (1) MX2023000439A (es)
PE (1) PE20231296A1 (es)
WO (1) WO2022008643A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183276A1 (en) * 2022-03-22 2023-09-28 University Of Southern California Adjunctive treatment of mycobacterial diseases
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
DK2301544T3 (da) 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
EP1626742A1 (en) 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilization of dispersions of nanoparticulate active agents with gamma radiation
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
NZ563819A (en) 2005-05-25 2011-01-28 Janssen Pharmaceutica Nv Process for preparing (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-napthalenyl-beta-phenyl-3-quinolineethanol (R207910)
US20090176813A1 (en) 2006-06-23 2009-07-09 Lieven Elvire Colette Baert Aqueous suspensions of tmc278
US9421194B2 (en) * 2010-04-05 2016-08-23 Rutgers, The State University Of New Jersey Lung targeting dual drug delivery system
ES2823805T3 (es) 2011-04-15 2021-05-10 Janssen Pharmaceutica Nv Nanosuspensiones de fármacos secadas por congelamiento
EP3651736B1 (en) 2017-07-14 2021-06-23 Janssen Pharmaceutica NV Long-acting formulations

Also Published As

Publication number Publication date
CN115867259A (zh) 2023-03-28
EP4178546A1 (en) 2023-05-17
BR112023000220A2 (pt) 2023-01-31
US20230241051A1 (en) 2023-08-03
PE20231296A1 (es) 2023-08-22
WO2022008643A1 (en) 2022-01-13
KR20230038521A (ko) 2023-03-20
CO2023001340A2 (es) 2023-02-27
JP2023533014A (ja) 2023-08-01
AU2021303490A1 (en) 2023-03-09
CA3182425A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
MX2023000439A (es) Formulaciones a largo plazo.
PH12020500076A1 (en) Long-acting formulations
JOP20200160A1 (ar) محاليل معلقة مائية للمركبات المسمى تي ام سي 278
ECSP22018209A (es) Nanopart?culas lip?dicas mejoradas para el suministro de ?cidos nucleicos
MX2018011627A (es) Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
MX2020001734A (es) Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7).
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CR8569A (es) Inhibidores de integrasa de vih
BR112012033077B8 (pt) Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MA32030B1 (fr) Vaccins anti-malaria
NZ757711A (en) Antimicrobial compounds, compositions, and uses thereof
MX2022013865A (es) Materiales sintéticos similares a los lípidos para la administración al cerebro.
DOP2021000073A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
PH12021550836A1 (en) Intratumor injection formulation
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EP4295917A3 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
MX2021007485A (es) Formulaciones orales de branaplam.
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
EA202090287A1 (ru) Составы пролонгированного действия
JOP20220038A1 (ar) عوامل مضادة للملاريا
GEP20227372B (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
MX2012003424A (es) Tratamiento y prevencion de infeccion por el virus de inmunodeficiencia humana.
MX2020013032A (es) Composiciones farmaceuticas a base de fructanos de agave.
MX2022001023A (es) Compuestos de aminotiolester y usos de los mismos.